Table 1 The clinical data of the patients

From: Characterisation of blood-derived exosomal hTERT mRNA secretion in cancer patients: a potential pan-cancer marker

Primary site (number)

Median age, years (minimum–maximum)

Male (%)

Stage

Histology

Mean (s.d.)

Median (minimum–maximum)

% of patients with high hTERT mRNA a

Bladder (7)

74 (55–84)

100%

III=14.3%

IV=85.7%

SCC=14.3%

TCC=85.7%

18.3 (29.8)

3 (0.8–79.6)

42.86

Breast (16)

60.5 (26–83)

0%

Unk=6.2%

II=6.2%

III=12.6%

IV=75%

Carcinoma, NOS=6.2%

Adenocarcinoma=93.8%

9.7 (19.2)

11.5 (0.1–55.9)

62.50

CLL (9)

75 (61–80)

66.7%

—

—

10.9 (13.4)

9 (0.1–41.7)

55.56

CRC (17)

70 (42–85)

29.4%

III=5.9%

IV=94.1%

Adenocarcinoma=100%

14.9 (15.3)

13.2 (0.3–53)

70.59

Endometrium and ovary (4)

68 (65–77)

0%

III=50%

IV=50%

Adenocarcinoma=100%

12.2 (16.4)

5.6 (1.2–36.3)

50.00

Gastric and oesophagus (7)

71 (62–81)

42.6%

Unk=14.3%

II=14.3%

III=28.5%

IV=42.9%

SCC=14.3%

Adenocarcinoma=85.7%

9.2 (9.2)

7.1 (0.04–27.1)

71.43

Head and neck (5)

55 (43–73)

80%

III=40%

IV=60%

Carcinoma, NOS=20%

SCC=80%

10.6 (10.2)

11 (0.9–26.8)

60.00

Kidney (1)

62

100%

IV=100%

RCC=100%

0.24

0.24

0.00

Acute leukaemia (12)

67 (34–87)

75%

—

ALL=16.7%

AML=83.3%

6.4 (9.9)

1 (0.1–34.2)

41.67

Lung (19)

64 (38–83)

52.6%

I=5.3%

III=15.8%

IV=78.9%

Carcinoma, NOS=10.5%

SCC=5.3%

Adenocarcinoma=68.4%

Small cell carcinoma=15.8%

15.9 (20.3)

10.3 (0.04–83.6)

63.16

Lymphoma (11)

42 (19–84)

63.6%

Unk=54.5%

I=9.1%

IV=36.4%

HL=18.2%

DLBCL=27.3

Other=54.5%

26.7 (41.2)

4 (0.1–121.9)

63.64

Melanoma (2)

55 (53–57)

50%

III=50%

IV=50%

Melanoma=100%

26.5 (47.6)

36.5 (2.9–70.2)

50.00

Multiple myeloma (3)

74 (51–80)

66.7%

—

—

3.2 (2.6)

4.5 (0.2–4.9)

66.67

Otherb (5)

43 (32–58)

80%

II=20%

IV=80%

SCC=20%

Adenocarcinoma=40%

Other=40%

10.5 (6.2)

13.9 (0.4–14.7)

80.00

Pancreas and biliary tract (12)

66.5 (51–91)

33.3%

Unk=8.3%

III=8.3%

IV=83.4%

Carcinoma, NOS=25%

Adenocarcinoma=75%

12.2 (20.6)

3.9 (0.2–72.9)

58.33

Prostate (3)

81 (77–90)

100%

IV=100%

Adenocarcinoma=100%

0.9 (0.9)

0.67 (0.2–1.9)

0.00

  1. Abbreviations: ALL, acute lymphocytic leukaemia; AML=acute myelocytic leukaemia; CLL=chronic lymphocytic leukaemia; CRC=colorectal cancer; DLBCL=diffuse large B-cell lymphoma; HL=Hodgkin’s lymphoma; NOS=not otherwise specified; RCC=renal cell carcinoma; RQ=relative quantification; SCC=squamous cell carcinoma; TCC=transitional cell carcinoma; Unk.=unknown.
  2. aHigh hTERT mRNA levels refer to RQ levels that are 3 or higher.
  3. bOther tumours included: cervix squamous cell carcinoma, hepatocellular carcinoma, testicular germ cell tumour and unknown primary.
Back to article page